Susquehanna International Group, LLP Cogent Biosciences, Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 15, 2024	SELL	$6.01 - $9.04 $76,327 - $114,807	-12,700 Reduced 26.57%	35,100 $295,000
Q1 2024 May 07, 2024	BUY	$4.38 - $9.02 $50,808 - $104,632	11,600 Added 32.04%	47,800 $321,000
Q4 2023 Feb 14, 2024	BUY	$4.06 - $10.08 $79,169 - $196,560	19,500 Added 116.77%	36,200 $212,000
Q3 2023 Nov 14, 2023	BUY	$9.69 - $13.34 $161,823 - $222,778	16,700 New	16,700 $162,000
Q4 2022 Feb 14, 2023	SELL	$10.65 - $14.84 $242,820 - $338,352	-22,800 Reduced 50.67%	22,200 $256,000
Q3 2022 Nov 14, 2022	SELL	$9.39 - $16.99 $16,902 - $30,581	-1,800 Reduced 3.85%	45,000 $671,000
Q2 2022 Aug 15, 2022	BUY	$3.92 - $9.73 $183,456 - $455,364	46,800 New	46,800 $422,000

159

114M

104K

163K

Ticker COGT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,758,300
Market Cap $710M
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.